查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1662674

2030 年關節內粘稠補充療法市場預測：按產品類型、來源、分銷管道、應用和地區進行全球分析

Viscosupplementation Market Forecasts to 2030 - Global Analysis By Product Type (Hyaluronic Acid (HA) Injections, Non-Hyaluronic Acid Products and Other Product Types), Source, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球關節內粘稠補充療法市場預計在 2024 年達到 54 億美元，到 2030 年將達到 105 億美元，預測期內的複合年成長率為 11.5%。關節內粘稠補充療法治療方法主要用於治療膝關節骨關節炎 (OA)，其中凝膠狀物質（通常是透明質酸 (HA)）注射到受影響的關節中以補充天然滑液。 HA透過恢復關節液的潤滑性能來幫助減輕疼痛並提高活動能力。當止痛藥和物理治療等保守措施無法提供足夠的緩解時，通常會使用這種治療方法。此治療方法創傷性極小，只需要在幾週內注射幾次即可。

根據美國疾病管制與預防中心2020年4月發表的《骨關節炎》論文顯示，美國約有3,250萬人美國骨關節炎。除此之外，62%的女性患有骨關節炎。

骨關節炎發生率增加

骨關節炎越來越常見，尤其是在膝蓋等負重關節。患有這種疾病的人數日益增多，對有效治療方法的需求也日益增加。關節內粘稠補充療法是一種非侵入性手術治療方法，已成為緩解症狀和改善關節活動性的熱門選擇。由於骨關節炎影響了數百萬人，預測期內對關節內粘稠補充療法等可靠療法的需求可能會持續成長。

缺乏報銷政策

高昂的治療費用和有限的保險覆蓋範圍可能會阻礙患者獲得關節內粘稠補充療法注射。缺乏全面的報銷選擇可能會阻止患者選擇這種手術，特別是在醫療保險覆蓋有限的地區。這種成本障礙可能會減緩關節內粘稠補充療法療法作為骨關節炎治療方法的廣泛應用。克服此類報銷挑戰對於確保更廣泛的市場滲透至關重要。

微創手術的採用率不斷提高

由於患者和醫療保健提供者優先考慮侵入性較小且恢復時間較短的治療方法，因此關節內粘稠補充療法療法成為傳統外科手術干預的引人注目的替代方案。該手術是非侵入性的，並且具有減輕疼痛和改善活動能力的潛力，使其成為治療骨關節炎的良好選擇。隨著關節內粘稠補充療法有望進一步獲得認可並擴大市場佔有率。

可能的副作用

關節內粘稠補充療法會引起關節疼痛、腫脹和感染等副作用。這些副作用的風險可能會阻止一些患者選擇關節內粘稠補充療法作為治療方法。此外，如果副作用無法妥善控制，可能會對治療的聲譽產生負面影響，並讓患者和醫療保健提供者產生猶豫。解決安全問題和加強病患教育對於最大限度地減少這種威脅至關重要。

COVID-19 的影響

COVID-19 疫情關節內粘稠補充療法。一方面，由於診所關門、醫療資源重新分配，包括關節內粘稠補充療法注射等選擇性治療程序的速度減慢。同時，此次疫情凸顯了非手術治療對治療骨關節炎等慢性病的重要性，隨著醫療系統的適應，需求將會恢復。隨著人們越來越重視減少就診次數和促進門診治療，關節內粘稠補充療法很可能在後疫情時代作為首選治療方法持續成長。

預計預測期內透明質酸（HA）注射市場規模將達到最大。

預計透明質酸 (HA) 注射劑將在預測期內佔據最大的市場佔有率，因為它具有恢復滑液、提供潤滑和減少骨關節炎關節發炎的能力。其已被證實的有效性和在關節內粘稠補充療法中的長期使用關節內粘稠補充療法成為患者和醫療保健提供者的首選。作為最成熟、應用最廣泛的關節內粘稠補充療法，HA 注射療法預計將在未來幾年佔據市場主導地位。

預計預測期內非動物性食品部分將以最高的複合年成長率成長。

由於人們對動物源產品的潛在風險的擔憂日益增加，預計非動物源部分將在預測期內呈現最高的成長率，使得非動物源透明質酸成為患者更具吸引力的選擇。這些產品適合對動物性治療有過敏反應或有道德問題的患者。非動物關節內粘稠補充療法產品的需求正在成長，因為它們被認為更安全、更永續，為製造商提供了市場擴張機會並滿足了消費者的偏好。

比最大的地區

在預測期內，預計北美將佔據最大的市場佔有率，這得益於人們對骨關節炎治療的高度認知和高昂的醫療支出。預計北美的需求將持續存在，因為北美民眾關節內粘稠補充療法有強烈的偏好，而且老齡化人口眾多。此外，預計美國和加拿大領先製造商和研究機構的存在將在整個預測期內推動關節內粘稠補充療法市場的創新和成長。

複合年成長率最高的地區

預計預測期內亞太地區將呈現最高的複合年成長率。快速的都市化、醫療保健機會的增加以及人口老化導致該地區骨關節炎的盛行率上升。在中國、印度和日本等國家，由於醫療意識的增強和醫療設施的改善，關節內粘稠補充療法的採用正在成長。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球關節內粘稠補充療法市場（依產品類型分類）

  • 介紹
  • 透明質酸 (HA) 注射
    • 單次注射產品
    • 多種注塑產品
    • 五注塑產品
  • 不含玻尿酸的產品
    • 膠原蛋白注射劑
    • 富血小板血漿
    • 幹細胞注射
  • 其他

6. 全球關節內粘稠補充療法市場（依來源分類）

  • 介紹
  • 動物來源
  • 非動物來源

7. 全球關節內粘稠補充療法市場按分銷管道分類

  • 介紹
  • 直接銷售
  • 診所
  • 零售藥局和藥局
  • 網路藥局和電子商務平台
  • 其他

8. 全球關節內粘稠補充療法市場（按應用）

  • 介紹
  • 骨關節炎
  • 創傷性關節炎
  • 類風濕性關節炎
  • 膝關節骨關節炎
  • 其他

9. 全球關節內粘稠補充療法市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章 主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Anika Therapeutics, Inc.
  • Aptissen
  • Bioventus LLC
  • Chugai Pharmaceuticals Co., Ltd.
  • DePuy Synthes
  • F.Hoffmann-La Roche Ltd.
  • Ferring Pharmaceuticals BV
  • Fidia Farmaceutici SpA
  • Johnson & Johnson Services, Inc.
  • LG Life Sciences Ltd.
  • Lifecore Biomedical
  • OrthogenRx Inc.
  • Sanofi
  • Seikagaku Corp.
  • Smith & Nephew PLC
  • Zimmer Biomet
Product Code: SMRC28535

According to Stratistics MRC, the Global Viscosupplementation Market is accounted for $5.4 billion in 2024 and is expected to reach $10.5 billion by 2030 growing at a CAGR of 11.5% during the forecast period. Viscosupplementation is a medical treatment for osteoarthritis (OA), primarily in the knee that involves injecting a gel-like substance, typically hyaluronic acid (HA), into the affected joint to supplement the natural synovial fluid. HA helps reduce pain and improve mobility by restoring the fluid's lubricating properties. This treatment is often used when conservative measures like pain medications or physical therapy have not provided sufficient relief. The procedure is minimally invasive, requiring just a few injections spaced over several weeks.

According to an article published by the Centers for Disease Control and Prevention in April 2020, titled "Osteoarthritis", about 32.5 million people in the United States are suffering from osteoarthritis. In addition to this, 62% of women suffer from osteoarthritis.

Market Dynamics:

Driver:

Rising incidence of osteoarthritis

Osteoarthritis is becoming more prevalent, especially in weight-bearing joints like the knee. The increasing number of people suffering from this condition is creating a growing demand for effective treatment options. Viscosupplementation, offering a non-invasive alternative to surgery, has gained popularity as an option to alleviate symptoms and improve joint mobility. With osteoarthritis affecting millions, the need for reliable therapies, such as viscosupplementation, will continue to expand during the forecast period.

Restraint:

Lack of reimbursement policies

The high cost of the treatment and limited insurance coverage can hinder patient access to viscosupplementation injections. The absence of comprehensive reimbursement options may deter patients from opting for the procedure, especially in areas with stricter healthcare policies. This cost-related barrier can slow the widespread adoption of viscosupplementation as a treatment for osteoarthritis. Overcoming these reimbursement challenges will be crucial to ensuring broader market penetration.

Opportunity:

Increasing adoption of minimally invasive procedures

As patients and healthcare providers prioritize less invasive treatment options with quicker recovery times, viscosupplementation offers a compelling alternative to traditional surgical interventions. The procedure's non-invasive nature, coupled with its potential to reduce pain and improve mobility, positions it as a favorable choice for managing osteoarthritis. With the growing trend toward outpatient, minimally invasive procedures, viscosupplementation is expected to gain further traction, expanding its market share.

Threat:

Potential for adverse reactions

Viscosupplementation procedure can lead to side effects such as joint pain, swelling, or infection. The risk of these reactions may discourage some patients from choosing viscosupplementation as a treatment option. Additionally, adverse reactions, if not properly managed, could negatively impact the reputation of the treatment, creating hesitancy among both patients and healthcare providers. Addressing safety concerns and improving patient education is essential for minimizing this threat.

Covid-19 Impact

The Covid-19 pandemic had a mixed impact on the viscosupplementation market. On one hand, lockdowns and healthcare resource reallocations slowed elective procedures, including viscosupplementation injections, due to restricted access to clinics. On the other hand, the pandemic highlighted the importance of non-surgical treatments for managing chronic conditions like osteoarthritis, leading to a rebound in demand as healthcare systems adapted. With a growing focus on reducing hospital visits and promoting outpatient care, viscosupplementation may see sustained growth as a preferred treatment in the post-pandemic era.

The hyaluronic acid (HA) injections segment is expected to be the largest during the forecast period

The hyaluronic acid (HA) injections segment is expected to account for the largest market share during the forecast period owing to its ability to restore synovial fluid, providing lubrication and reducing inflammation in osteoarthritis -affected joints. Its proven effectiveness and long-standing use in viscosupplementation have made it the preferred choice for both patients and healthcare providers. As the most established and widely used form of viscosupplementation, the HA injections segment is anticipated to dominate the market in the coming years.

The non-animal source segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the non-animal source segment is predicted to witness the highest growth rate due to increasing concerns over the potential risks of animal-derived products, non-animal-based hyaluronic acid offers a more attractive option for patients. These products cater to individuals who may have allergies or ethical concerns related to animal-based treatments. The demand for non-animal sourced viscosupplementation products is rising as they are perceived to be safer and more sustainable, offering manufacturers a growing opportunity to expand their market reach and meet consumer preferences.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to high awareness of osteoarthritis treatments, and significant healthcare spending. With a strong preference for non-invasive treatments like viscosupplementation, North America's large aging population will drive continued demand. Furthermore, the presence of leading manufacturers and research institutions in the United States and Canada will support innovation and the growth of the viscosupplementation market throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid urbanization, increasing healthcare access, and a growing elderly population are contributing to the rising prevalence of osteoarthritis in this region. Countries like China, India, and Japan are seeing greater adoption of viscosupplementation due to rising healthcare awareness and improved medical facilities.

Key players in the market

Some of the key players in Viscosupplementation market include Anika Therapeutics, Inc., Aptissen, Bioventus LLC, Chugai Pharmaceuticals Co., Ltd., DePuy Synthes, F.Hoffmann-La Roche Ltd., Ferring Pharmaceuticals B.V., Fidia Farmaceutici S.p.A, Johnson & Johnson Services, Inc., LG Life Sciences Ltd., Lifecore Biomedical, OrthogenRx Inc., Sanofi, Seikagaku Corp., Smith & Nephew PLC and Zimmer Biomet.

Key Developments:

In November 2024, Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies.

In December 2024, Smith+Nephew announced its CORIOGRAPH Pre-Op Planning and Modeling Services are now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration.

Product Types Covered:

  • Hyaluronic Acid (HA) Injections
  • Non-Hyaluronic Acid Products
  • Other Product Types

Sources Covered:

  • Animal Source
  • Non-Animal Source

Distribution Channels Covered:

  • Direct Sales
  • Clinics
  • Retail Pharmacies & Drugstores
  • Online Pharmacies & E-commerce Platforms
  • Other Distribution Channels

Applications Covered:

  • Osteoarthritis
  • Post-Traumatic Arthritis
  • Rheumatoid Arthritis
  • Knee Osteoarthritis
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viscosupplementation Market, By Product Type

  • 5.1 Introduction
  • 5.2 Hyaluronic Acid (HA) Injections
    • 5.2.1 Single-Injection Products
    • 5.2.2 Multiple-Injection Products
    • 5.2.3 Five-Injection Products
  • 5.3 Non-Hyaluronic Acid Products
    • 5.3.1 Collagen-Based Injections
    • 5.3.2 Platelet-Rich Plasma
    • 5.3.3 Stem Cell-Based Injections
  • 5.4 Other Product Types

6 Global Viscosupplementation Market, By Source

  • 6.1 Introduction
  • 6.2 Animal Source
  • 6.3 Non-Animal Source

7 Global Viscosupplementation Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Direct Sales
  • 7.3 Clinics
  • 7.4 Retail Pharmacies & Drugstores
  • 7.5 Online Pharmacies & E-commerce Platforms
  • 7.6 Other Distribution Channels

8 Global Viscosupplementation Market, By Application

  • 8.1 Introduction
  • 8.2 Osteoarthritis
  • 8.3 Post-Traumatic Arthritis
  • 8.4 Rheumatoid Arthritis
  • 8.5 Knee Osteoarthritis
  • 8.6 Other Applications

9 Global Viscosupplementation Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Anika Therapeutics, Inc.
  • 11.2 Aptissen
  • 11.3 Bioventus LLC
  • 11.4 Chugai Pharmaceuticals Co., Ltd.
  • 11.5 DePuy Synthes
  • 11.6 F.Hoffmann-La Roche Ltd.
  • 11.7 Ferring Pharmaceuticals B.V.
  • 11.8 Fidia Farmaceutici S.p.A
  • 11.9 Johnson & Johnson Services, Inc.
  • 11.10 LG Life Sciences Ltd.
  • 11.11 Lifecore Biomedical
  • 11.12 OrthogenRx Inc.
  • 11.13 Sanofi
  • 11.14 Seikagaku Corp.
  • 11.15 Smith & Nephew PLC
  • 11.16 Zimmer Biomet

List of Tables

  • Table 1 Global Viscosupplementation Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Viscosupplementation Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Viscosupplementation Market Outlook, By Hyaluronic Acid (HA) Injections (2022-2030) ($MN)
  • Table 4 Global Viscosupplementation Market Outlook, By Single-Injection Products (2022-2030) ($MN)
  • Table 5 Global Viscosupplementation Market Outlook, By Multiple-Injection Products (2022-2030) ($MN)
  • Table 6 Global Viscosupplementation Market Outlook, By Five-Injection Products (2022-2030) ($MN)
  • Table 7 Global Viscosupplementation Market Outlook, By Non-Hyaluronic Acid Products (2022-2030) ($MN)
  • Table 8 Global Viscosupplementation Market Outlook, By Collagen-Based Injections (2022-2030) ($MN)
  • Table 9 Global Viscosupplementation Market Outlook, By Platelet-Rich Plasma (2022-2030) ($MN)
  • Table 10 Global Viscosupplementation Market Outlook, By Stem Cell-Based Injections (2022-2030) ($MN)
  • Table 11 Global Viscosupplementation Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 12 Global Viscosupplementation Market Outlook, By Source (2022-2030) ($MN)
  • Table 13 Global Viscosupplementation Market Outlook, By Animal Source (2022-2030) ($MN)
  • Table 14 Global Viscosupplementation Market Outlook, By Non-Animal Source (2022-2030) ($MN)
  • Table 15 Global Viscosupplementation Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 16 Global Viscosupplementation Market Outlook, By Direct Sales (2022-2030) ($MN)
  • Table 17 Global Viscosupplementation Market Outlook, By Clinics (2022-2030) ($MN)
  • Table 18 Global Viscosupplementation Market Outlook, By Retail Pharmacies & Drugstores (2022-2030) ($MN)
  • Table 19 Global Viscosupplementation Market Outlook, By Online Pharmacies & E-commerce Platforms (2022-2030) ($MN)
  • Table 20 Global Viscosupplementation Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
  • Table 21 Global Viscosupplementation Market Outlook, By Application (2022-2030) ($MN)
  • Table 22 Global Viscosupplementation Market Outlook, By Osteoarthritis (2022-2030) ($MN)
  • Table 23 Global Viscosupplementation Market Outlook, By Post-Traumatic Arthritis (2022-2030) ($MN)
  • Table 24 Global Viscosupplementation Market Outlook, By Rheumatoid Arthritis (2022-2030) ($MN)
  • Table 25 Global Viscosupplementation Market Outlook, By Knee Osteoarthritis (2022-2030) ($MN)
  • Table 26 Global Viscosupplementation Market Outlook, By Other Applications (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.